Xiang Hong, Zhang Qingkai, Qi Bing, Tao Xufeng, Xia Shilin, Song Huiyi, Qu Jialin, Shang Dong
College (Institute) of Integrative Medicine, Dalian Medical UniversityDalian, China.
Department of General Surgery, The First Affiliated Hospital of Dalian Medical UniversityDalian, China.
Front Pharmacol. 2017 Apr 25;8:216. doi: 10.3389/fphar.2017.00216. eCollection 2017.
Acute pancreatitis (AP) is a commonly occurring gastrointestinal disorder. An increase in the annual incidence of AP has been observed, and it causes acute hospitalization and high mortality. The diagnosis and treatment guidelines for AP recommend conservative medical treatments focused on reducing pancreatic secretion and secondary injury, as a primary therapeutic approach. Unfortunately, the existing treatment options have limited impact on the incidence and severity of AP due to the complex and multifaceted pathological process of this disease. In recent decades, Chinese herbal medicines (CHMs) have been used as efficient therapeutic agents to attenuate AP in Asian countries. Despite early cell culture, animal models, and clinical trials, CHMs are capable of interacting with numerous molecular targets participating in the pathogenesis of AP; however, comprehensive, up-to-date communication in this field is not yet available. This review focuses on the pharmacological activities of CHMs against AP and and the underlying mechanisms. A computational prediction of few selected and promising plant-derived molecules (emodin, baicalin, resveratrol, curcumin, ligustrazine, and honokiol) to target numerous proteins or networks involved in AP was initially established based on a network pharmacology simulation. Moreover, we also summarized some potential toxic natural products for pancreas in order to more safe and reasonable medication. These breakthrough findings may have important implications for innovative drug research and the future development of treatments for AP.
急性胰腺炎(AP)是一种常见的胃肠道疾病。据观察,AP的年发病率有所上升,它会导致急性住院和高死亡率。AP的诊断和治疗指南推荐以减少胰腺分泌和继发性损伤为重点的保守药物治疗作为主要治疗方法。不幸的是,由于该疾病复杂多面的病理过程,现有的治疗选择对AP的发病率和严重程度影响有限。近几十年来,中草药(CHMs)在亚洲国家已被用作减轻AP的有效治疗药物。尽管进行了早期的细胞培养、动物模型和临床试验,但CHMs能够与参与AP发病机制的众多分子靶点相互作用;然而,该领域尚未有全面、最新的交流。本综述重点关注CHMs抗AP的药理活性及其潜在机制。基于网络药理学模拟,最初建立了对几种选定且有前景的植物源分子(大黄素、黄芩苷、白藜芦醇、姜黄素、川芎嗪和厚朴酚)针对参与AP的众多蛋白质或网络的计算预测。此外,我们还总结了一些对胰腺有潜在毒性的天然产物,以便更安全合理地用药。这些突破性发现可能对创新药物研究和AP治疗的未来发展具有重要意义。